IL6 and cancer: Further, many researches proved that anti IL-6 therapy showed potential benefits for treating various human cancers including glioma (109, 110), Sumida et al. found that an anti-IL-6 receptor monoclonal antibody (mAb) could eliminate MDSCs and inhibit tumor growth by enhancing T-cell responses, and that its therapeutic effect was enhanced by combination with gemcitabine (111).